Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy
Lung Cancer International · 2012
DOI: 10.1155/2012/587424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung Cancer International, 2012. Verfasst von A Hallqvist und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 405 30 Gothenberg, Sweden ; Department of On…. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Background
The main attention regarding prognostic and predictive markers in NSCLC directs towards the EGFR-targeted pathway, where the most studied genetic alterations include EGFR mutations, EGFR copy number, and KRAS mutations. We wanted to explore the prognostic impact of mutated KRAS in the stage III setting treated with high-dose radiochemotherapy.
Methods
Samples were obtained from patients participating in two prospective studies of locally advanced NSCLC receiving combined radiochemotherapy: the RAKET study, a randomized phase II study where patients were treated with induction chemotherapy (carboplatin/paclitaxel) followed by concurrent radiochemotherapy, and the Satellite trial, a phase II study with induction chemotherapy (cisplatin/docetaxel) followed by radiotherapy concurrent cetuximab. The samples were analysed regarding KRAS mutations, EGFR mutations, and EGFR FISH positivity.
Results
Patients with mutated KRAS had a significantly inferior survival, which maintained its significance in a multivariate analysis when other possible prognostic factors were taken into account. The prevalence of KRAS mutations, EGFR mutations, and EGFR FISH positivity were 28.8%, 7.5%, and 19.7%, respectively.
Conclusion
Mutated KRAS is an independent negative prognostic factor for survival in NSCLC stage III disease treated with combined radiochemotherapy. The prevalence of KRAS mutations and EGFR mutations are as expected in this Scandinavian population.
Autor:innen und Institutionen
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 405 30 Gothenberg, Sweden ; Department of Oncology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
- Department of Pathology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
- Department of Cytogenetics, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 405 30 Gothenberg, Sweden.
Zitieren
APA
Hallqvist, A., Enlund, F., Andersson, C., Sjögren, H., Hussein, A., Holmberg, E., & Nyman, J. (2012). Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy. Lung Cancer International. https://doi.org/10.1155/2012/587424
Vancouver
Hallqvist A, Enlund F, Andersson C, Sjögren H, Hussein A, Holmberg E, et al. Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy. Lung Cancer International. 2012. doi:10.1155/2012/587424
BibTeX
@article{Hallqvist2012,
author = {Hallqvist, A and Enlund, F and Andersson, C and Sjögren, H and Hussein, A and Holmberg, E and Nyman, J},
title = {Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy},
journal = {Lung Cancer International},
year = {2012},
doi = {10.1155/2012/587424}
}
EUVIMED